Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain

Summary

This study is to provide safety information of hemoporfin during the post-marketing period as required by China Food and Drug Administration (CFDA) regulations in order to identify any potential drug related treatment factors in the Chinese population, such as unknown/unexpected adverse reactions, the incidence of adverse reactions under the routine drug uses.

Timeline

Start

2017-08-31

Primary completion

2023-04-19

Completion

2023-04-19

Drugs

Indications

No indication recorded.